Henry E. Pelish Insider Trading Activity
Henry E. Pelish has been net-selling over the last 12 months with 0 purchases and 22 sales across 1 company.
NUVL is the most-traded position with 22 trades. The largest single transaction was a sale of NUVL for $2.4M on Mar 12, 2026.
Performance Scorecard
Forward stock performance after each transaction by Henry E. Pelish. Buy returns measure price movement after open-market purchases; sell-avoided measures the loss avoided after open-market sales. Success rate counts trades where the insider's direction was right.
| PERIOD | AVG BUY RETURN | AVG SELL AVOIDED | SUCCESS RATE | TRADES |
|---|---|---|---|---|
| 30 days | — | -3.7% | 21% | 29 |
| 90 days | — | -12.8% | 7% | 29 |
| 120 days | — | -17.1% | 0% | 27 |
Performance based on stock price movement after each transaction date. Past results do not predict future returns. Not financial advice.
Price & Trades
Pro: Trade MarkersNUVL · Nuvalent, Inc.
🔒 Subscribe to see trade entries
Pro members see exactly when Henry E. Pelish bought and sold NUVL.
Upgrade to ProRecent Trades
| DATE | TICKER | TYPE | SHARES | PRICE | VALUE | Δ OWNED | ROLE | FILING |
|---|---|---|---|---|---|---|---|---|
Apr 9, 2026 | NUVL | Sell | 2,193 | $104.27 | $229K | −3.2% | Chief Scientific Officer | |
Apr 9, 2026 | NUVL | Sell | 900 | $105.00 | $95K | −1.4% | Chief Scientific Officer | |
Mar 13, 2026 | NUVL | Sell | 1,703 | $99.71 | $170K | −2.5% | Chief Scientific Officer | |
Mar 13, 2026 | NUVL | Sell | 804 | $97.89 | $79K | −1.1% | Chief Scientific Officer | |
Mar 13, 2026 | NUVL | Sell | 2,597 | $98.83 | $257K | −3.7% | Chief Scientific Officer | |
Mar 12, 2026 | NUVL | Sell | 24,189 | $97.79 | $2.4M | −24.0% | Chief Scientific Officer | |
Mar 12, 2026 | NUVL | Sell | 5,505 | $98.44 | $542K | −7.2% | Chief Scientific Officer | |
Mar 12, 2026 | NUVL | Sell | 306 | $99.12 | $30K | −0.4% | Chief Scientific Officer | |
Jan 6, 2026 | NUVL | Sell | 189 | $98.40 | $19K | −0.3% | Chief Scientific Officer | |
Jan 6, 2026 | NUVL | Sell | 1,106 | $96.75 | $107K | −1.6% | Chief Scientific Officer | |
Jan 6, 2026 | NUVL | Sell | 1,369 | $97.33 | $133K | −2.0% | Chief Scientific Officer | |
Jan 5, 2026 | NUVL | Sell | 186 | $98.52 | $18K | −0.3% | Chief Scientific Officer | |
Jan 5, 2026 | NUVL | Sell | 513 | $96.06 | $49K | −0.7% | Chief Scientific Officer | |
Jan 5, 2026 | NUVL | Sell | 660 | $96.85 | $64K | −0.9% | Chief Scientific Officer | |
Jan 5, 2026 | NUVL | Sell | 1,137 | $97.96 | $111K | −1.6% | Chief Scientific Officer | |
Oct 15, 2025 | NUVL | Sell | 14,205 | $90.04 | $1.3M | −17.7% | Chief Scientific Officer | |
Oct 14, 2025 | NUVL | Sell | 400 | $87.39 | $35K | −0.6% | Chief Scientific Officer | |
Oct 14, 2025 | NUVL | Sell | 1,167 | $84.98 | $99K | −1.7% | Chief Scientific Officer | |
Oct 14, 2025 | NUVL | Sell | 866 | $86.11 | $75K | −1.3% | Chief Scientific Officer | |
Oct 13, 2025 | NUVL | Sell | 7,637 | $89.81 | $686K | −10.4% | Chief Scientific Officer | |
Sep 10, 2025 | NUVL | Sell | 3,725 | $78.83 | $294K | −5.3% | Chief Scientific Officer | |
Aug 7, 2025 | NUVL | Sell | 5,500 | $74.85 | $412K | −8.3% | Chief Scientific Officer | |
Jul 10, 2025 | NUVL | Sell | 240 | $80.92 | $19K | −0.4% | Chief Scientific Officer | |
Jul 10, 2025 | NUVL | Sell | 5,260 | $79.94 | $420K | −7.9% | Chief Scientific Officer | |
Jul 9, 2025 | NUVL | Sell | 1,945 | $81.08 | $158K | −3.1% | Chief Scientific Officer | |
Jul 9, 2025 | NUVL | Sell | 200 | $81.90 | $16K | −0.3% | Chief Scientific Officer | |
Jun 27, 2025 | NUVL | Sell | 2,170 | $79.92 | $173K | −3.3% | Chief Scientific Officer | |
Jun 25, 2025 | NUVL | Sell | 8,630 | $79.87 | $689K | −12.0% | Chief Scientific Officer | |
Jun 6, 2025 | NUVL | Sell | 200 | $79.82 | $16K | −0.3% | Chief Scientific Officer |
Top Companies Traded
| TICKER | COMPANY | TRADES | TOTAL VOLUME |
|---|---|---|---|
| NUVL | Nuvalent, Inc. | 29 | $8.6M |
Other insiders at Nuvalent, Inc.
6 other tracked filers at NUVL.